Literature DB >> 26306594

Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.

Sebastian Ewen1, Markus R Meyer2, Bodo Cremers3, Ulrich Laufs3, Andreas G Helfer2, Dominik Linz3, Ingrid Kindermann3, Christian Ukena3, Michel Burnier4, Stefan Wagenpfeil5, Hans H Maurer2, Michael Böhm3, Felix Mahfoud6.   

Abstract

Renal denervation can reduce blood pressure in patients with uncontrolled hypertension. The adherence to prescribed antihypertensive medication following renal denervation is unknown. This study investigated adherence to prescribed antihypertensive treatment by liquid chromatography-high resolution tandem mass spectrometry in plasma and urine at baseline and 6 months after renal denervation in 100 patients with resistant hypertension, defined as baseline office systolic blood pressure ≥140 mmHg despite treatment with ≥3 antihypertensive agents. At baseline, complete adherence to all prescribed antihypertensive agents was observed in 52 patients, 46 patients were partially adherent, and two patients were completely non-adherent. Baseline office blood pressure was 167/88 ± 19/16 mmHg with a corresponding 24-h blood pressure of 154/86 ± 15/13 mmHg. Renal denervation significantly reduced office and ambulatory blood pressure at 6-month follow-up by 15/5 mmHg (p < 0.001/p < 0.001) and 8/4 mmHg (p < 0.001/p = 0.001), respectively. Mean adherence to prescribed treatment was significantly reduced from 85.0 % at baseline to 80.7 %, 6 months after renal denervation (p = 0.005). The blood pressure decrease was not explained by improvements in adherence following the procedure. Patients not responding to treatment significantly reduced their drug intake following the procedure. Adherence was highest for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta blockers (>90 %) and lowest for vasodilators (21 %). In conclusion, renal denervation can reduce office and ambulatory blood pressure in patients with resistant hypertension despite a significant reduction in adherence to antihypertensive treatment after 6 months.

Entities:  

Keywords:  Adherence to drug treatment; Liquid chromatography–high resolution tandem mass spectrometry; Renal denervation; Resistant hypertension; Sympathetic nervous system

Mesh:

Substances:

Year:  2015        PMID: 26306594     DOI: 10.1007/s00392-015-0905-5

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  31 in total

Review 1.  Analytical toxicology.

Authors:  Hans H Maurer
Journal:  EXS       Date:  2010

2.  Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.

Authors:  Dirk K Wissenbach; Markus R Meyer; Daniela Remane; Armin A Weber; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2010-11-16       Impact factor: 4.142

3.  Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches.

Authors:  Andreas G Helfer; Alain Turcant; David Boels; Séverine Ferec; Bénédicte Lelièvre; Jessica Welter; Markus R Meyer; Hans H Maurer
Journal:  Drug Test Anal       Date:  2014-06-22       Impact factor: 3.345

4.  Renal denervation: symply trapped by complexity?

Authors:  Felix Mahfoud; Thomas Felix Lüscher
Journal:  Eur Heart J       Date:  2014-11-16       Impact factor: 29.983

5.  Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study.

Authors:  Ján Rosa; Petr Widimský; Petr Toušek; Ondřej Petrák; Karol Čurila; Petr Waldauf; František Bednář; Tomáš Zelinka; Robert Holaj; Branislav Štrauch; Zuzana Šomlóová; Miloš Táborský; Jan Václavík; Eva Kociánová; Marian Branny; Igor Nykl; Otakar Jiravský; Jiří Widimský
Journal:  Hypertension       Date:  2014-11-24       Impact factor: 10.190

6.  Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy?

Authors:  Felix Mahfoud; Elazer R Edelman; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

7.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

Review 8.  Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy.

Authors:  Bernard Waeber; François Feihl
Journal:  EuroIntervention       Date:  2013-05       Impact factor: 6.534

9.  Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  24 in total

Review 1.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

Review 2.  Hypertension: history and development of established and novel treatments.

Authors:  Milan Wolf; Sebastian Ewen; Felix Mahfoud; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-06-27       Impact factor: 5.460

Review 3.  Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs.

Authors:  Franco Rabbia; Chiara Fulcheri; Silvia Di Monaco; Michele Covella; Elisa Perlo; Marco Pappaccogli; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-09

4.  Second denervation in a patient with resistant hypertension.

Authors:  Jose Carlos Prado; Dayan Salado; Luis Miguel Ruilope; Julian Segura
Journal:  Clin Res Cardiol       Date:  2016-06-08       Impact factor: 5.460

5.  Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension.

Authors:  Christian Ott; Christoph Kopp; Anke Dahlmann; Axel Schmid; Peter Linz; Alexander Cavallaro; Matthias Hammon; Tilmann Ditting; Roland Veelken; Michael Uder; Jens Titze; Roland E Schmieder
Journal:  Clin Res Cardiol       Date:  2017-08-28       Impact factor: 5.460

Review 6.  Hypertension up to date: SPRINT to SPYRAL.

Authors:  Saarraaken Kulenthiran; Sebastian Ewen; Michael Böhm; Felix Mahfoud
Journal:  Clin Res Cardiol       Date:  2017-03-22       Impact factor: 5.460

7.  Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.

Authors:  Rosa L de Jager; Erik M van Maarseveen; Michiel L Bots; Peter J Blankestijn
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

8.  Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department.

Authors:  Candace D McNaughton; Nancy J Brown; Russell L Rothman; Dandan Liu; Edmond K Kabagambe; Phillip D Levy; Wesley H Self; Alan B Storrow; Sean P Collins; Christianne L Roumie
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

Review 9.  Renal Denervation: Is It Ready for Prime Time?

Authors:  Lucas Lauder; Milan A Wolf; Sean S Scholz; Mathias Hohl; Felix Mahfoud; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2019-07-05       Impact factor: 2.931

Review 10.  Current Status of Renal Denervation in Hypertension.

Authors:  Alexander Briasoulis; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.